Allergy Therapeutics (LON:AGY) Hits New 1-Year Low – What’s Next?

Allergy Therapeutics plc (LON:AGY) hit a new 52-week low during mid-day trading on Wednesday. The company traded as low as GBX 4.50 and last traded at GBX 4.50, with a volume of 1800 shares traded. The stock had previously closed at GBX 4.75.

Allergy Therapeutics Stock Performance

The firm has a market capitalization of £316.63 million, a PE ratio of -5.15, a P/E/G ratio of -30.70 and a beta of 0.83. The company has a debt-to-equity ratio of 629.58, a current ratio of 1.13 and a quick ratio of 1.48. The firm has a fifty day moving average price of GBX 5.28 and a 200 day moving average price of GBX 7.66.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.